Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
MIB-626 by Metro International Biotech for Friedreich Ataxia: Likelihood of Approval
MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Friedreich Ataxia. According to GlobalData,...
Data Insights
MIB-626 by Metro International Biotech for Acute Renal Failure (ARF) (Acute Kidney Injury): Likelihood of Approval
MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Acute Renal Failure (ARF) (Acute...